Neuropathic Pain News and Research RSS Feed - Neuropathic Pain News and Research

Lyfebulb, Immune collaborate to increase awareness of bullous pemphigoid

Lyfebulb, Immune collaborate to increase awareness of bullous pemphigoid

Lyfebulb, the International Pemphigus Pemphigoid Foundation (IPPF) and Immune Pharmaceuticals Inc., announced a collaboration to increase awareness of unmet needs in treating bullous pemphigoid last night at an event attended by more than sixty patients, physicians, scientists and other interested parties. [More]

Choice of HRQoL measure for chronic pain matters

Researchers recommend the use of generic health-related quality of life measures to determine pain-related burden of disease, but consideration needs to be given to which one is used. [More]
Glenmark plans to set up new manufacturing facility at Monroe Corporate Center, USA

Glenmark plans to set up new manufacturing facility at Monroe Corporate Center, USA

Glenmark Pharmaceuticals Ltd, a research-driven, global, integrated pharmaceutical company, plans to set up a new manufacturing facility in the US. [More]
Virobay announces closing of expanded Series B second tranche financing

Virobay announces closing of expanded Series B second tranche financing

Virobay, Inc., a clinical stage pharmaceutical company with a platform of cathepsin protease inhibitors being developed for the treatment of neuropathic pain, autoimmune disease and fibrosis, today announced the closing of an expanded Series B second tranche financing of $8.0 million. [More]
Japanese SF-MPQ valid for neuropathic and non-neuropathic pain

Japanese SF-MPQ valid for neuropathic and non-neuropathic pain

Researchers have developed a Japanese translated version of the Short-Form McGill Pain Questionnaire-2 that shows good reliability and validity for discriminating between chronic neuropathic and non-neuropathic pain. [More]
Researchers create combination drug that controls both tumor growth and metastasis

Researchers create combination drug that controls both tumor growth and metastasis

Researchers at UC Davis, University of Massachusetts and Harvard Medical School have created a combination drug that controls both tumor growth and metastasis. By combining a COX-2 inhibitor, similar to Celebrex, and an epoxide hydrolase (sEH) inhibitor, the drug controls angiogenesis (blood vessel formation), limiting a tumor's ability to grow and spread. [More]
NeuroMetrix receives marketing certification from TÜV SÜD Japan for NC-stat DPNCheck

NeuroMetrix receives marketing certification from TÜV SÜD Japan for NC-stat DPNCheck

NeuroMetrix, Inc., an innovative health care company that develops wearable medical technology and point-of-care tests to help patients and physicians manage chronic pain, nerve diseases, and sleep disorders, today reported the receipt of marketing certification from Technischer Überwachungs-Verein SÜD Japan Ltd. for NC-stat DPNCheck as a Class II Designated Controlled Medical Device as defined in the technical standards of the Japan Ministry of Health, Labor, and Welfare. [More]
SLU researchers discover pain pathway and potential way to block it

SLU researchers discover pain pathway and potential way to block it

In a recently published study in the Journal of Biological Chemistry, Saint Louis University professor of pharmacological and physiological sciences Daniela Salvemini, Ph.D. describes two discoveries: a molecular pathway by which a painful chemotherapy side effect happens and a drug that may be able to stop it. [More]
American Pain Society, Pain Research Forum provide grant support for PRF's "Papers of the Week"

American Pain Society, Pain Research Forum provide grant support for PRF's "Papers of the Week"

The American Pain Society announced today it has begun a collaboration with the Pain Research Forum in which APS will provide grant support for PRF's "Papers of the Week" website postings of new papers in pain research, which are published in peer-reviewed journals covering pain, neuroscience and related disciplines. [More]
BioLineRx announces in-licensing of BL-1110 compound for treatment of neuropathic pain

BioLineRx announces in-licensing of BL-1110 compound for treatment of neuropathic pain

BioLineRx Ltd., a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today it has in-licensed BL-1110, a novel compound for the treatment of neuropathic pain. [More]
International researchers discover genetic component of Idiopathic Generalized Epilepsy

International researchers discover genetic component of Idiopathic Generalized Epilepsy

An international team of researchers has discovered a significant genetic component of Idiopathic Generalized Epilepsy (IGE), the most common form of epilepsy. [More]
Discovery may lead to relief for victims of range of neurological disorders

Discovery may lead to relief for victims of range of neurological disorders

University of Toronto biologists leading an investigation into the cells that regulate proper brain function, have identified and located the key players whose actions contribute to afflictions such as epilepsy and schizophrenia. [More]
Glenmark Pharmaceuticals opens new monoclonal antibody manufacturing facility in Switzerland

Glenmark Pharmaceuticals opens new monoclonal antibody manufacturing facility in Switzerland

Glenmark Pharmaceuticals S.A (GPSA), a wholly-owned subsidiary of Glenmark Pharmaceuticals Limited, India (GPL), announced the opening of its new cGMP compliant monoclonal antibody manufacturing facility in La Chaux-de-Fonds, Switzerland. T [More]
Nektar reports etirinotecan pegol Phase 2 study results in patients with Avastin-refractory high-grade glioma

Nektar reports etirinotecan pegol Phase 2 study results in patients with Avastin-refractory high-grade glioma

Nektar Therapeutics announced today new data from an investigator-sponsored Phase 2 study of NKTR-102 (etirinotecan pegol) in patients with Avastin-refractory high-grade glioma conducted at Stanford Cancer Institute under the direction of Lawrence Recht, M.D., Professor of Neurology and Neurosurgery, with co-investigator Seema Nagpal, M.D., Clinical Assistant Professor of Neurology and Neurological Sciences, Stanford School of Medicine. [More]
New antibody appears to block sensations of pain, itching in mouse model

New antibody appears to block sensations of pain, itching in mouse model

Duke University researchers have found an antibody that simultaneously blocks the sensations of pain and itching in studies with mice. [More]
NeuroMetrix announces marketing launch of NC-Stat DPNCheck in Japan

NeuroMetrix announces marketing launch of NC-Stat DPNCheck in Japan

NeuroMetrix, Inc., an innovative health care company that develops wearable medical technology and point-of-care tests to help patients and physicians manage chronic pain, nerve diseases, and sleep disorders, today reported the marketing launch in Japan of NC-stat® DPNCheck®. [More]
UNC researchers find new enzyme target for treating chronic pain

UNC researchers find new enzyme target for treating chronic pain

Researchers at the UNC School of Medicine have found a new target for treating chronic pain: an enzyme called PIP5K1C. [More]
Researchers show how cone snails venom inhibits neuronal calcium channels to reduce neuropathic pain

Researchers show how cone snails venom inhibits neuronal calcium channels to reduce neuropathic pain

The venom from marine cone snails, used to immobilize prey, contains numerous peptides called conotoxins, some of which can act as painkillers in mammals. A recent study in The Journal of General Physiology provides new insight into the mechanisms by which one conotoxin, Vc1.1, inhibits pain. [More]
Neuropathic pain features common in knee OA

Neuropathic pain features common in knee OA

Enough patients with knee osteoarthritis experience pain with neuropathic characteristics to warrant attempts to diagnose and classify these features, say researchers. [More]
Acorda gets FDA Complete Response Letter for PLUMIAZ Nasal Spray NDA

Acorda gets FDA Complete Response Letter for PLUMIAZ Nasal Spray NDA

Acorda Therapeutics, Inc. today announced that the U.S. Food and Drug Administration has issued a Complete Response Letter (CRL) for the New Drug Application (NDA) for PLUMIAZ (diazepam) Nasal Spray for the treatment of people with epilepsy who experience cluster seizures. [More]